BioAge Labs’ (BIOA) Buy Rating Reaffirmed at BTIG Research

BioAge Labs (NASDAQ:BIOA)‘s stock had its “buy” rating reiterated by equities researchers at BTIG Research in a research report issued on Monday,Benzinga reports. They currently have a $40.00 price target on the stock. BTIG Research’s target price points to a potential upside of 342.48% from the company’s previous close.

A number of other analysts have also recently weighed in on the stock. Needham & Company LLC decreased their price target on shares of BioAge Labs from $50.00 to $35.00 and set a “buy” rating for the company in a research note on Friday. Wall Street Zen lowered shares of BioAge Labs from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. Jefferies Financial Group set a $21.00 target price on shares of BioAge Labs in a report on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a research note on Tuesday, July 21st. Finally, Roth Capital reiterated a “buy” rating and set a $25.00 price target on shares of BioAge Labs in a research note on Friday. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $36.57.

BioAge Labs Price Performance

BIOA opened at $9.04 on Monday. The firm has a market cap of $401.83 million, a price-to-earnings ratio of -3.77 and a beta of 0.94. BioAge Labs has a 52 week low of $4.11 and a 52 week high of $25.95. The business’s 50 day moving average is $20.61 and its two-hundred day moving average is $19.53.

BioAge Labs (NASDAQ:BIOA) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.19. The company had revenue of $2.77 million during the quarter. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%. Equities analysts expect that BioAge Labs will post -2.68 EPS for the current fiscal year.

Institutional Trading of BioAge Labs

Several large investors have recently modified their holdings of the business. Geode Capital Management LLC lifted its stake in BioAge Labs by 60.8% in the 2nd quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock valued at $1,873,000 after buying an additional 171,426 shares in the last quarter. Walleye Capital LLC acquired a new position in BioAge Labs in the 2nd quarter valued at about $64,000. Marshall Wace LLP boosted its stake in shares of BioAge Labs by 324.7% during the 2nd quarter. Marshall Wace LLP now owns 226,789 shares of the company’s stock worth $937,000 after purchasing an additional 173,388 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of BioAge Labs by 85.6% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock valued at $54,000 after buying an additional 5,976 shares during the last quarter. Finally, Ameriprise Financial Inc. acquired a new stake in BioAge Labs during the second quarter worth approximately $182,000.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.